Albireo Pharma (NASDAQ:ALBO) Posts Earnings Results, Misses Expectations By $0.46 EPS

Albireo Pharma (NASDAQ:ALBOGet Rating) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($2.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.58) by ($0.46), Fidelity Earnings reports. Albireo Pharma had a negative return on equity of 73.93% and a negative net margin of 72.02%. During the same quarter last year, the firm earned ($1.90) EPS.

Albireo Pharma Price Performance

ALBO opened at $24.93 on Tuesday. Albireo Pharma has a 52-week low of $17.81 and a 52-week high of $37.63. The stock has a market capitalization of $482.64 million, a P/E ratio of -14.16 and a beta of 0.89. The company has a debt-to-equity ratio of 0.07, a quick ratio of 7.20 and a current ratio of 7.26. The company’s 50-day simple moving average is $22.04 and its two-hundred day simple moving average is $27.08.

Institutional Investors Weigh In On Albireo Pharma

Institutional investors have recently added to or reduced their stakes in the stock. Rice Hall James & Associates LLC lifted its position in Albireo Pharma by 3.7% in the first quarter. Rice Hall James & Associates LLC now owns 474,991 shares of the biopharmaceutical company’s stock worth $14,169,000 after buying an additional 16,980 shares during the last quarter. Swiss National Bank increased its stake in shares of Albireo Pharma by 7.8% during the first quarter. Swiss National Bank now owns 38,800 shares of the biopharmaceutical company’s stock valued at $1,157,000 after buying an additional 2,800 shares during the period. JPMorgan Chase & Co. grew its stake in Albireo Pharma by 20.1% in the first quarter. JPMorgan Chase & Co. now owns 8,010 shares of the biopharmaceutical company’s stock valued at $239,000 after purchasing an additional 1,341 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Albireo Pharma by 15.0% in the first quarter. Bank of New York Mellon Corp now owns 96,568 shares of the biopharmaceutical company’s stock valued at $2,881,000 after purchasing an additional 12,600 shares during the last quarter. Finally, MetLife Investment Management LLC grew its stake in Albireo Pharma by 54.2% in the first quarter. MetLife Investment Management LLC now owns 9,864 shares of the biopharmaceutical company’s stock valued at $294,000 after purchasing an additional 3,466 shares during the last quarter. 82.99% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ALBO has been the subject of several recent analyst reports. Wedbush reiterated a “buy” rating and set a $72.00 price objective on shares of Albireo Pharma in a research report on Tuesday, May 17th. Robert W. Baird dropped their price target on shares of Albireo Pharma from $66.00 to $40.00 in a research report on Tuesday. StockNews.com downgraded shares of Albireo Pharma from a “hold” rating to a “sell” rating in a report on Monday, May 30th. Finally, HC Wainwright decreased their price objective on shares of Albireo Pharma from $80.00 to $54.00 in a report on Tuesday.

About Albireo Pharma

(Get Rating)

Albireo Pharma, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases.

Read More

Earnings History for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.